SalubrisBio Competitors and Similar CompaniesClear all

SalubrisBio's competitors and similar companies include NeoPhore, Mary Crowley Cancer Research, American Cancer Society and BioNTech.

	SalubrisBio SalubrisBio is a clinical-stage biotechnology company discovering and developing antibody and protein-based therapeutics.	NeoPhore NeoPhore is a healthcare company that targets cancer neoantigen research.	Mary Crowley Cancer Research Mary Crowley Cancer Research is a cancer research center.	American Cancer Society American Cancer Society (ACS) is an organization that specializes in cancer prevention.	BioNTech BioNTech is a biotechnology company developing immunotherapies for cancer and infectious diseases.
Founding Date	Founding Date 2016	Founding Date 2017	Founding Date 1997	Founding Date 1913	Founding Date 2008
Type	Type Subsidiary	Type Private	Type Private	Type Private	Type Public
Tags	Tags Healthcare clinical research oncology	Tags Healthcare clinical research oncology	Tags Healthcare clinical research oncology	Tags Healthcare clinical research oncology therapy	Tags Healthcare clinical research drug development oncology
Locations	Locations Gaithersburg, US HQ	Locations Babraham, GB HQ Altrincham, GB	Locations Dallas, US HQ Abilene, US Dallas, US	Locations Kennesaw, US HQ Hagatna, GU Arecibo, PR Caguas, PR Mayagüez, PR Ponce, PR San Juan, PR see more	Locations Mainz, DE HQ Melbourne, AU Wien, AT Shanghai, CN Paris, FR Berlin, DE Berlin, DE see more
Employees	Employees 34	Employees 225% increase	Employees 724% decrease	Employees 7,754	Employees 6,772
Financial
Revenue (est.)	Revenue (est.) N/A	Revenue (est.) N/A	Revenue (est.) N/A	Revenue (est.) $768.1m (FY, 2021)	Revenue (est.) €2.9b (FY, 2025)
Cost of goods	Cost of goods N/A	Cost of goods N/A	Cost of goods N/A	Cost of goods $442.5m (FY, 2021)	Cost of goods €260.4m (FY, 2025)
Gross profit	Gross profit N/A	Gross profit N/A	Gross profit N/A	Gross profit $325.6m (FY, 2021)	Gross profit €2.7b (FY, 2025)
Net income	Net income N/A	Net income N/A	Net income N/A	Net income $69.3m (FY, 2021)	Net income (€1.1b) (FY, 2025)
Funding
Total funding raised	Total funding raised $ 32m	Total funding raised $ 25m	Total funding raised N/A	Total funding raised N/A	Total funding raised N/A